SAB Biotherapeutics presented additional Phase 1 clinical and mechanistic data for its lead candidate SAB‑142 at the 21st Immunology of Diabetes Society (IDS) Congress in Brisbane, Australia, on April 22, 2026. The presentation highlighted that all four type 1 diabetes (T1D) participants receiving SAB‑142 showed C‑peptide preservation, with three of the four exhibiting a super‑responder profile and evidence of CD4⁺ T‑cell exhaustion.
The data also demonstrated improved glycemic control, with continuous glucose monitoring showing a rise in time‑in‑range from 73 % at baseline to 85 % at Day 120, without an increase in exogenous insulin use. These findings reinforce SAB‑142’s intended mechanism of action—inducing T‑cell exhaustion to preserve beta‑cell function—and support the company’s claim of a potentially safe, long‑term immunotherapy for T1D.
The Phase 1 results are a key operational milestone for the pre‑revenue company, providing early evidence of efficacy and safety that will inform the ongoing Phase 2b SAFEGUARD trial. The data will be reviewed by the FDA and topline results from SAFEGUARD are expected in the second half of 2027.
SAB Biotherapeutics is supported by recent financing, including an $85 million public offering in March 2026 and a $175 million private placement in July 2025, giving the company a runway to fund the Phase 2b trial and future development. The company remains pre‑revenue, but the capital raised positions it to continue advancing its pipeline.
"We were excited to present these new findings to the global scientific community at the Immunology of Diabetes Society Congress, as they provided deeper insights into how SAB‑142's immunologic effects may translate into meaningful benefit for people with T1D," said CEO Samuel J. Reich. "In sharing these Phase 1 data, we continue to build confidence in SAB‑142's differentiated and potentially best‑in‑class product profile as a disease‑modifying therapy for T1D. We look forward to reporting topline data from our registrational Phase 2b SAFEGUARD trial in the 2H 2027." Chief Medical Officer Alexandra Kropotova added, "These new results from the participants with T1D in the Phase 1 trial reinforce SAB‑142's intended mechanism of action, inducing T cell exhaustion that correlates with anticipated C‑peptide response levels, and improved glycemic control not driven by exogenous insulin. These findings are consistent with what has been observed with rabbit ATG. Importantly, our data demonstrated sustained immunomodulation without immunodepletion with both induction and maintenance dosing, a finding that directly supports SAB‑142's differentiation as a potentially safe and effective long‑term immunotherapy for patients across all stages of T1D."
SAB‑142 is positioned against other immune‑modifying therapies such as rabbit anti‑thymocyte immunoglobulin (rATG) and Sanofi's Tzield. Unlike Tzield, which is approved only for Stage 2 T1D, SAB‑142 is being developed for both Stage 2 and Stage 3 disease, potentially expanding its addressable market. The company’s proprietary platform, which uses genetically engineered cattle to produce human immunoglobulin G, is a key differentiator that may allow for safer redosing and a superior safety profile compared to existing therapies.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.